FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122134619> ?p ?o ?g. }

• W3122134619 endingPage "761" @default.
• W3122134619 startingPage "754" @default.
• W3122134619 abstract "Meropenem, a broad-spectrum carbapenem, is frequently used to treat severe bacterial infections in critically ill children. Recommendations for meropenem doses in adult infections are available; however, few studies have been published regarding the use of meropenem in children with sepsis, especially in those receiving continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO). We aimed to investigate the pharmacokinetic (PK) parameters of meropenem in children with sepsis receiving extracorporeal life support (ECLS).This was a prospective observational clinical study of children with sepsis receiving ECMO or CRRT in the paediatric intensive care unit (PICU) of a children's hospital. The enrolled children received 20 mg/kg meropenem infusion over 1 hour, every 8 hours, and were grouped into children receiving ECMO, children receiving CRRT and children receiving neither ECMO nor CRRT. Plasma meropenem concentrations were determined using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The key PK parameters were determined using the non-compartmental approach.Twenty-seven patients were finally enrolled. The eCLCR of the CRRT group was lower than that of the ECMO group. The values of elimination half-life (t1/2 ), area under the plasma concentration-time curve (AUCtau ), area under the plasma concentration-time curve from time zero to infinity (AUC0-∞ ), and total clearance (CL) in the ECMO group were not different from those of the other groups (all p > 0.05). However, the AUCtau (p = 0.0137) and AUC0-∞ (p = 0.0234) significantly decreased after filtration through a hemofiltration membrane in patients receiving CRRT.No significant alterations in the PK parameters of meropenem occurred in children with sepsis administered ECMO and/or CRRT. Further investigations including PK modelling could provide evidence for appropriate meropenem dosing regimens during ECLS administration." @default.
• W3122134619 created "2021-02-01" @default.
• W3122134619 creator A5002835054 @default.
• W3122134619 creator A5005776144 @default.
• W3122134619 creator A5012428737 @default.
• W3122134619 creator A5034205421 @default.
• W3122134619 creator A5045203159 @default.
• W3122134619 creator A5050579428 @default.
• W3122134619 creator A5056248574 @default.
• W3122134619 date "2021-01-21" @default.
• W3122134619 modified "2023-09-30" @default.
• W3122134619 title "Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study" @default.
• W3122134619 cites W1995610280 @default.
• W3122134619 cites W2041638228 @default.
• W3122134619 cites W2044526347 @default.
• W3122134619 cites W2062328478 @default.
• W3122134619 cites W2090642347 @default.
• W3122134619 cites W2104876473 @default.
• W3122134619 cites W2106443705 @default.
• W3122134619 cites W2119289429 @default.
• W3122134619 cites W2131361484 @default.
• W3122134619 cites W2150286011 @default.
• W3122134619 cites W2152073293 @default.
• W3122134619 cites W2309350026 @default.
• W3122134619 cites W2486226358 @default.
• W3122134619 cites W2748061698 @default.
• W3122134619 cites W2759292809 @default.
• W3122134619 cites W2791088950 @default.
• W3122134619 cites W2795131008 @default.
• W3122134619 cites W2981349837 @default.
• W3122134619 cites W4245690870 @default.
• W3122134619 doi "https://doi.org/10.1111/jcpt.13344" @default.
• W3122134619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8248190" @default.
• W3122134619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33476064" @default.
• W3122134619 hasPublicationYear "2021" @default.
• W3122134619 type Work @default.
• W3122134619 sameAs 3122134619 @default.
• W3122134619 citedByCount "9" @default.
• W3122134619 countsByYear W31221346192021 @default.
• W3122134619 countsByYear W31221346192022 @default.
• W3122134619 countsByYear W31221346192023 @default.
• W3122134619 crossrefType "journal-article" @default.
• W3122134619 hasAuthorship W3122134619A5002835054 @default.
• W3122134619 hasAuthorship W3122134619A5005776144 @default.
• W3122134619 hasAuthorship W3122134619A5012428737 @default.
• W3122134619 hasAuthorship W3122134619A5034205421 @default.
• W3122134619 hasAuthorship W3122134619A5045203159 @default.
• W3122134619 hasAuthorship W3122134619A5050579428 @default.
• W3122134619 hasAuthorship W3122134619A5056248574 @default.
• W3122134619 hasBestOaLocation W31221346191 @default.
• W3122134619 hasConcept C112705442 @default.
• W3122134619 hasConcept C126322002 @default.
• W3122134619 hasConcept C177713679 @default.
• W3122134619 hasConcept C188816634 @default.
• W3122134619 hasConcept C2776376669 @default.
• W3122134619 hasConcept C2776685102 @default.
• W3122134619 hasConcept C2776858399 @default.
• W3122134619 hasConcept C2778063415 @default.
• W3122134619 hasConcept C2778384902 @default.
• W3122134619 hasConcept C2778865887 @default.
• W3122134619 hasConcept C2778939556 @default.
• W3122134619 hasConcept C2779375183 @default.
• W3122134619 hasConcept C2779541074 @default.
• W3122134619 hasConcept C2779915274 @default.
• W3122134619 hasConcept C42219234 @default.
• W3122134619 hasConcept C501593827 @default.
• W3122134619 hasConcept C71924100 @default.
• W3122134619 hasConcept C86803240 @default.
• W3122134619 hasConcept C89423630 @default.
• W3122134619 hasConcept C94665300 @default.
• W3122134619 hasConceptScore W3122134619C112705442 @default.
• W3122134619 hasConceptScore W3122134619C126322002 @default.
• W3122134619 hasConceptScore W3122134619C177713679 @default.
• W3122134619 hasConceptScore W3122134619C188816634 @default.
• W3122134619 hasConceptScore W3122134619C2776376669 @default.
• W3122134619 hasConceptScore W3122134619C2776685102 @default.
• W3122134619 hasConceptScore W3122134619C2776858399 @default.
• W3122134619 hasConceptScore W3122134619C2778063415 @default.
• W3122134619 hasConceptScore W3122134619C2778384902 @default.
• W3122134619 hasConceptScore W3122134619C2778865887 @default.
• W3122134619 hasConceptScore W3122134619C2778939556 @default.
• W3122134619 hasConceptScore W3122134619C2779375183 @default.
• W3122134619 hasConceptScore W3122134619C2779541074 @default.
• W3122134619 hasConceptScore W3122134619C2779915274 @default.
• W3122134619 hasConceptScore W3122134619C42219234 @default.
• W3122134619 hasConceptScore W3122134619C501593827 @default.
• W3122134619 hasConceptScore W3122134619C71924100 @default.
• W3122134619 hasConceptScore W3122134619C86803240 @default.
• W3122134619 hasConceptScore W3122134619C89423630 @default.
• W3122134619 hasConceptScore W3122134619C94665300 @default.
• W3122134619 hasIssue "3" @default.
• W3122134619 hasLocation W31221346191 @default.
• W3122134619 hasLocation W31221346192 @default.
• W3122134619 hasLocation W31221346193 @default.
• W3122134619 hasOpenAccess W3122134619 @default.
• W3122134619 hasPrimaryLocation W31221346191 @default.
• W3122134619 hasRelatedWork W1985470865 @default.
• W3122134619 hasRelatedWork W2029824841 @default.

• next